Expression of serum miR-638 in breast cancer and its clinical value
10.13602/j.cnki.jcls.2019.12.06
- VernacularTitle:miR-638在乳腺癌血清中的表达及其临床应用价值
- Author:
Linhai LI
1
;
Bin XIAO
1
;
Xi CHEN
2
;
Zhaohui SUN
1
;
Zhenzhan KUANG
1
;
Qiwu WEN
3
Author Information
1. Department of Laboratory Medicine, General Hospital of Southern Theater, PLA
2. School of Basic Medicine, Guangzhou University of Traditional Chinese Medicine
3. Department of Health Service, General Hospital of Southern Theater, PLA
- Publication Type:Journal Article
- Keywords:
breast cancer;
miR-638;
tumor marker;
screening
- From:
Chinese Journal of Clinical Laboratory Science
2019;37(12):901-904
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression levels of serum miR-638 in the patients with breast cancer and its clinical value.
Methods:One hundred and fifty-two patients with breast cancer were selected as the disease group, and 102 healthy persons as the control group. The expression levels of miR-638 in their serum samples were detected by the quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and the expression levels of serum miR-638 in the patients with different pathological stages, before and after operation, and before and after chemotherapy were compared. The diagnosis efficacy of serum miR-638 alone and in combination with CEA, CA125, CA15-3 for breast cancer was analyzed by the ROC curve and Z test.
Results:The expression levels of serum miR-638 in the breast cancer group (3.6 [1.3～10.5]) were significantly lower than that in the control group (79.0 [52.5～120.8],P＜0.01). The linear regression analysis showed that chemotherapy and pathological staging were the main factors influencing the expression levels of serum miR-638. The area under the ROC curve (AUC ROC ) of serum miR-638 in the diagnosis of breast cancer was 0.954. When the cut-off value of serum miR-638 was 27.47, its sensitivity and specificity for the diagnosis of breast cancer were 94% and 86.2%, respectively. The area under the ROC curve (AUC ROC ) of serum miR-638 combined with CEA, CA125 and CA15-3 in the diagnosis of breast cancer was 0.978 8. When the combined cut-off value was 0.29, their sensitivity and specificity for the diagnosis of breast cancer were 95.4% and 89.5%, respectively. There was no significant difference in the AUC ROC between miR-638 alone and combined screening (Z=1.68,P=0.091).
Conclusion:Serum miR-638 may be a potential molecular marker for the screening of breast cancer.
